The use of prostate biopsies was developed in parallel with progress in our knowledge of prostate cancer and the use of prostate-speci®c antigen (PSA). Prostate biopsies were initially indicated for the diagnosis of cancer, by the perineal approach under general anesthesia. Nowadays prostate biopsies are not only for diagnostic purposes but also to determine the prognosis, particularly before radical prostatectomy. They are performed in patients with elevated PSA levels, by the endorectal approach, sometimes under local anesthesia.
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The gold standard is the sextant biopsy technique described by Hodge 4,5 , which is best to diagnose prostate cancer, particularly in case of T1c disease (patients with serum PSA elevation). 6±13 Patients with a strong suspicion of prostate cancer from a negative series of biopsies can undergo a second series IRYIS with transition zone biopsy 16, 17 or lateral biopsy.
18,19
Karakiewicz et al 20 and Uzzo et al 21 proposed that the number of prostate biopsies should depend on prostate volume to improve the positivity rate. After the diagnosis of prostate cancer, initial therapy will depend on several prognostic factors. In the case of radical prostatectomy, the results of sextant biopsy provide a wealth of information. 22, 23 The aim of this report is to present the information given by prostate biopsy in the staging of prostate cancer.
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Histological results

Gleason score
The Gleason et al 24 score is considered an important prognostic factor in prostate cancer. Gleason 25 suggested that prostate tumors had relatively stable degrees of malignancy and growth rates, rather than a steady increase in malignancy with time. However, while small prostate tumors are often composed of a single grade (usually Gleason grade 2 or 3), most palpable cancers contain multiple grades which are arranged in heterogeneous and unpredictable regions, as shown by Atara et al. 26 The highest tumor grade is not usually found within the core of the tumor. The Gleason score at biopsy corresponds to the score at radical prostatectomy in 30± 70% of cases, while the Gleason score at prostatectomy is underestimated at 33±45% of cases. 27±29 In a series of 180 cases, we found a correlation between the Gleason score on biopsies and radical prostatectomy specimens in 38.8% of cases, an underestimation in 43.8% of cases, and an overestimation in 17% of cases. As regards cellular grades, the results were respectively 58.3%, 25% and 16.6% (biopsy and radical prostatectomy specimens were studied by the same pathologist). Fernandes et al
30
showed that a well-differentiated tumor in the biopsy core is a poor predictor of a well-differentiated neoplasm or organ-con®ned disease after surgical treatment, and that a high Gleason score in the biopsy is usually associated with disease outside the prostate and a poorly differentiated tumor in the prostatectomy specimen. The use of an 18-gauge biopsy needle rather than a 14-gauge needle does not affect these results, even if the grade accuracy falls in case of low-grade and small tumors. 27 Parker 31 preferred to use a 14-gauge biopsy needle because the correlation was better, 48 proposed these biopsies for patients with a Gleason score of more than 4, a PSA level of more than 10 ngaml or a clinical stage of T2b or more, and suggested that patients with positive seminal vesicle biopsies should undergo pelvic lymph node dissection. Guillonneau et al 49 proposed these biopsies when the two basal sextant biopsies were positive because, in this case, 70% of patients had seminal vesicle invasion and no other discriminatory preoperative parameters (clinical stage, number of positive biopsies and PSA).
Visualisation of the prostate capsule and perineural invasion
The prostate capsule can be visualized by biopsy. Biopsies can be performed tangentially to the peripheral area or the needle may be inserted 1 or 2 mm outside the echographic limits of the gland to obtain both glandular edges and periprostatic tissue. Perforation of the capsule is evident if carcinomatous material is present in the periprostatic tissue. Biopsies conducted according to Ravery et al 50,51 have a positive predictive value of 94% for extracapsular involvement. It has been suggested that the inability of prostate cancer to invade the perineural space could indicate a less aggressive pro®le. 52 Bostwick et al 53 demonstrated that perineural invasion correlated with capsular perforation and seminal vesicle invasion but, like Ravery et al, 51 he showed that it was not the best predictive factor relative to serum PSA and the Gleason score on biopsies. Bastacky et al 54 restricted the de®nition of perineural invasion to cases with more than one involved nerve or nerve involvement of a diameter of 0.1 mm or more. In this way the speci®city for capsular perforation increased to 99%, but the sensitivity fell to 9%. In combination with a high histologic tumor grade (Gleason score b 7) it could help to identify capsular penetration and to decide whether to sacri®ce or preserve all or part of the neurovascular bundle on the side of the needle biopsy.
Prostatic intra-epithelial neoplasia
Prostatic intra-epithelial neoplasia represents the precancerous end of the morphological continuum of cell proliferation within the prostatic ducts, ductules and acini. Prostatic intra-epithelial neoplasia has been divided into low-grade and high-grade forms. The presence of highgrade prostatic intra-epithelial neoplasia on needle biopsy is strongly predictive of carcinoma:
55±57 in 445 patients with prostatic intra-epithelial neoplasia, 19 out of 115 with low-grade PIN (20%) had prostatic carcinoma and 147 out of 232 (45.5%) had prostatic carcinoma. 58 , 59 Ellis et al 60 and Zlotta et al 61 recommended repeating biopsies in case of high-grade PIN whatever the PSA, and in case of low-grade PIN if the PSA is above 10 ngaml (N`4 ngaml).
Morphological results
Tumor volume
Stamey 62 suggested that tumors with a volume of less than 0.5 ml were probably too small to be treated (non signi®cant tumors), and that tumor volume was predictive of pathological stage. Different techniques are used to calculate tumor volume from PSA, the Gleason score and prostate ultrasound volume or the extent of positive biopsies. 63, 64 Studies have been performed to analyse the relationship between tumor volume and the length and percentage of cancer cells in positive biopsies and the number of positive biopsies.
Length of cancer positive biopsies
Prostate tumors are`signi®cant' if there is more than 3 mm of tumor on one or two sextant biopsies: when one biopsy is positive along more than 3 mm, and when the tumor volume is more than 0.5 ml. When two sextant biopsies are positive along more than 3 mm, the tumor volume is between 1 and 6 ml. 65 In contrast, according to Terris et al, 66 the tumor is not signi®cant if only one sextant biopsy is positive along less than 3 mm: whatever the number of positive biopsies, the tumor is not signi®cant if none are more than 3 mm long and the PSAD is below 0.15 and the Gleason grade is`4±5, 62 or if there are no biopsies more than 3 mm long with a PSAD below 0.1 and Gleason grade always below 3. 67 As a general rule, biopsies less than 2 mm long with a PSAD below 0.1 predict an organ-con®ned tumor, 68 while the total of the sextant biopsy associated with Gleason grade 4 or 5 predicts a non con®ned tumor. 62 However, Bruce et al 69 studied 49 patients with no core biopsies less than 2 mm in length and suggested that a microscopic focus of prostate adenocarcinoma in a needle biopsy specimen does not itself predict the pathologic stage or biological behaviour of a tumor.
Percentage of cancer cells in positive biopsies
The percentage of cancer cells, in combination with the PSA level and Gleason score, can predict the pathological stage. 53 The tumor is not signi®cant if there are less than 50% of cancer cells with a PSAD below 0.1, fewer than 3 positive biopsies and no Gleason grade 4 or 5. 62 Hammerer et al 70 combined the percentage of cancer cells in total biopsies with tumor grade to predict lymph node involvement and to identify patients who would not bene®t from lymph node dissection.
Because errors during sextant biopsy, Cupp et al 
Location of positive biopsies
The location of positive biopsies can provide abundant information: positive biopsies contralateral to a palpable nodule predict a large tumor. 73 Hodge et al 4 showed that 42% of T2a patients and 60% of T2b patients had positive contralateral biopsies. However, contralateral biopsies can be positive because of non signi®cant and incidental tumors. To identify the dominant side of the tumor, Stamey, 62 Dietrick et al 65 and Loch et al 74 used the total length of positive biopsies in each lobe of the prostate.
In case of a unilateral palpable lesion, Huland et al 75 preserved the neurovascular bundle only if contralateral biopsies were negative. Narayan et al 41 transformed clinical staging in biopsy-based staging, as described above, to predict, in combination with the PSA level and Gleason score, the pathological stage before radical prostatectomy. Bilateral basal biopsies, according to Dunzinger et al, 76 are an indication for lymph node dissection, while Guillonneau et al 49 considered them an indication for seminal vesicle biopsies because of the high risk of seminal vesicle involvement.
In a study of 180 radical prostatectomies, we examined the correlation between the location of positive biopsies and the location of the tumor in the prostatectomy specimen: we found a positive predictive value of 84% and a negative predictive value of 36%. These results could explain cases of high-risk cancers and negative biopsies, and also why negative results do not rule out the presence of cancer in the target region. 77 
Number of positive biopsies
The number of positive biopsies has been used in combination with the Gleason score and PSA to predict the ®nal pathological stage, the status of surgical margins and the risk of progression after radical prostatectomy. 78, 79 Numerous positive biopsies are predictive of extra-capsular disease: Pellar et al 80 showed that if the number of positive biopsies was above 3 and the Gleason score was above 6, the ®nal pathological stage was pT3. Ravery et al 50,51,81 demonstrated that a 66% positivity rate for prostate biopsies was predictive of uncon®ned tumors. Conversely, Epstein et al 82 suggested that the prostate tumor was not signi®cant when fewer than three biopsies were positive with a PSAD below 0.15, a Gleason score below 7 and fewer than 50% of cancer cells in each positive biopsy. According to Terris et al, 66 one positive biopsy with less than 3 mm of tumor re¯ects a non signi®cant tumor. However, Peller et al 80 and Ravery et al 83, 84 reported that one positive biopsy was not predictive of organ-con®ned disease.
Future research
The search for a speci®c marker in prostate biopsies to predict pathological stage before radical prostatectomy has been attempted with different approaches. Von Eschenbach et al 85 studied the correlation between the ploidy of prostate biopsy and prostatectomy specimens. Brawer 86 and Silberman et al 87 studied angiogenesis and found that biopsy angiogenesis re¯ected specimen angiogenesis, but no clinical applications have been proven.
Conclusion
Sextant biopsies provide abundant information on which to base the prognosis of radical prostatectomy and to choose the surgical approach for bilateral pelvic lymphadenectomy and neurovascular bundle preservation. Only positive results give really useful information: seminal vesicle invasion, perinervous involvement and a large number of positive biopsies are predictive of uncon®ned disease, but the opposite is not true. 
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